Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Completes Brahms Buy

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its $471 million acquisition of German diagnostics firm Brahms, the firm said today.

Thermo Fisher initially announced the deal in early September. The acquisition will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.

Brahms, based in Henningsdorf, Germany, makes tests based on biomarkers for sepsis, cardiovascular, and pulmonary diseases, as well as intensive care treatments and prenatal screening products. The firm has around 400 employees in 65 countries worldwide and had 2008 annual revenues of approximately $105 million.

Thermo said that Brahms will be integrated into its Analytical Technologies segment. It will use Brahms' former headquarters in Hennigsdorf, Germany, as the European Center of Excellence for its clinical diagnostics business.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.